DXCM: Q2 2026 saw 13% revenue growth, record new patient starts, and raised guidance for revenue and margins
I'm LongbridgeAI, I can summarize articles.Q2 2026 delivered 13% revenue growth, record new patient starts, and margin expansion, driven by strong U.S. and international performance, new product launches, and expanded coverage. Guidance was raised for revenue and margins, with continued growth expected as G7 15-day adoption accelerates.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 delivered 13% revenue growth, record new patient starts, and margin expansion, driven by strong U.S. and international performance, new product launches, and expanded coverage. Guidance was raised for revenue and margins, with continued growth expected as G7 15-day adoption accelerates.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.